RAS is the most common oncogene in cancer, and KRAS mutations are the predominant oncogene among the three RAS subtypes (HRAS, NRAS, and KRAS) (Hobbs et al., 2016), which was regarded as “untreatable” targets for a long time. This evidence concerns the gene KRAS and cancer.